XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Investments (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 15, 2024
USD ($)
Feb. 07, 2023
$ / shares
shares
Apr. 30, 2024
USD ($)
shares
Apr. 30, 2022
USD ($)
shares
Jul. 31, 2021
USD ($)
shares
May 31, 2021
USD ($)
shares
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Debt and Equity Securities, FV-NI [Line Items]                      
Realized gain             $ 25,459,000 $ (14,522,000) $ 27,763,000 $ 61,869,000  
Nimbus Therapeutics, LLC                      
Debt and Equity Securities, FV-NI [Line Items]                      
Non-marketable equity security             1,928,000   1,928,000   $ 1,928,000
Unrealized gain (loss)             0 2,165,000 0 2,165,000  
Realized gain                   147,322,000  
Morphic Holding, Inc.                      
Debt and Equity Securities, FV-NI [Line Items]                      
Proceeds from disposal of shares $ 47,588,000                    
Mark-to-market gain (loss)             19,140,000 (28,740,000) 23,474,000 (3,206,000)  
Marketable securities             0   0   24,114,000
Ajax Therapeutics, Inc                      
Debt and Equity Securities, FV-NI [Line Items]                      
Non-marketable equity security             4,700,000   4,700,000   1,700,000
Structure Therapeutics                      
Debt and Equity Securities, FV-NI [Line Items]                      
Mark-to-market gain (loss)             6,318,000 $ 12,052,000 4,289,000 $ 62,910,000  
Marketable securities             $ 58,588,000   $ 58,588,000   $ 55,509,000
Series B Preferred Stock | Structure Therapeutics                      
Debt and Equity Securities, FV-NI [Line Items]                      
Conversion ratio   1                  
Series B Preferred Stock | Ajax Therapeutics, Inc                      
Debt and Equity Securities, FV-NI [Line Items]                      
Number of preferred shares purchased (in shares) | shares           631,377          
Cash payments to purchase of shares           $ 1,700,000          
Series B Preferred Stock | Structure Therapeutics                      
Debt and Equity Securities, FV-NI [Line Items]                      
Number of preferred shares purchased (in shares) | shares       148,210 494,035            
Cash payments to purchase of shares       $ 600,000 $ 2,000,000            
Series C Preferred Stock | Ajax Therapeutics, Inc                      
Debt and Equity Securities, FV-NI [Line Items]                      
Number of preferred shares purchased (in shares) | shares     1,416,450                
Cash payments to purchase of shares     $ 3,000,000                
ADR | Structure Therapeutics                      
Debt and Equity Securities, FV-NI [Line Items]                      
Number of shares purchased (in shares) | shares   275,000                  
Purchase price (in USD per share) | $ / shares   $ 15.00                  
Stock split, conversion ratio   3